UK's HPA widens remit with top biologics R&D and standards body
This article was originally published in Clinica
Executive Summary
The UK's National Institute of Biological Standards (NIBSC) is to merge with the Health Protection Agency (HPA) in April 2009. The move will broaden the HPA's remit to cover safety in relation to the development and use of biological products, including those involving blood and tissues. The NISBC, which was behind the creation of the UK Stem Cell Bank, runs a "broad and vibrant research programme", produces "almost all the world's" international standards for biologics safety and effectiveness, and is said to be pre-eminent in areas of emerging importance, such as the H5N1 "avian flu" virus. The NIBSC's director, Stephen Inglis, spoke of the plans during the HPA's annual conference (University of Warwick, September 15-17).
You may also be interested in...
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.